Substance use disorder: contraceptive options counseling

What’s New in Contraception?

Contraceptive Technology Conference!

Biologic sexism of STIs

Excess breast cancer deaths after COVID-19

Contraception for patients with medical conditions

Pelvic Floor Dysfunction

Treating vulvodynia

Puzzling Over the Hurt Down-Under

Serious Mental Illness and Contraception

New 13-Cycle Vaginal Contraceptive System

The Future of Family Planning in Post-COVID America

New ASCCP Guidelines: Implications for FP

On the alert: mood disorders during 2020 stressors

Sex in the Time of COVID-19

Challenges old and new during the pandemic

Reproductive health in the time of Covid-19

Talking about toys

Missed Pills: The Problem That Hasn’t Gone Away

Find the “yes! . . . and” rather than “no” or “but”

Digital Family Planning: the Future is Now

Irregular Bleeding Due to Contraceptives

When she’s low on libido…

Ouch! Best approaches to menstrual pain

Contraceptive efficacy: understanding how user and method characteristics play their part

Strategizing treatment for chronic heavy menstrual bleeding


Untangling the literature on obesity and contraception

High tech apps for no-tech FABM

Menstrual exacerbation of other medical conditions

From Princeton University: Thomas James Trussell (1949-2018)

The Short and Long of IUD Use Duration

Selecting a Method When Guidance Isn’t Clear-cut

Healthcare in the Time of Digital Expansion

The Scoop on Two New FDA-Approved Contraceptive Methods

Pregnancy of unknown location—meeting the challenge

Big “yes” (with caveats) to CHCs during perimenopause

The role of IUDs (LNG IUDs, too!) in emergency contraception

Combined pills’ effect on mood disorders

Abortion in the U.S.: safe, declining, and under threat

Hope for ovarian cancer screening test

Breast cancer still a small risk with some hormonal contraceptives

New treatment modality for BV

Record rate of HPV-related throat cancer

Viruses in semen potentially transmissible

Don’t Abstain from Your Role in Abstinence

Teens births declining but geographic ‘hotspots’ defy trend

Online Medical Abortion Service Effective and Safe

Do Women Really Need to Wait That Long?

Reassuring news on depression and OC use

PMDD: Genetic clues may lead to improved treatment

Breast cancer risk when there is a family history

Body weight link to breast and endometrial cancers (and 11 others)

Family Planning in 2017 and Beyond

Make Me Cry: Depression Link (Again)?

Managing implant users’ bleeding and spotting

Zika: Updated guidance for providers

Pharmacist-prescribed contraceptives

Hot off the press! 2016 MEC and SPR

Zika virus fears prompt increased request for abortion in nations outlawing abortions

Opioid use epidemic among reproductive-age women

Good news on the family planning home front!

War Against Planned Parenthood Hurts Women

Win-win for both treatment and prevention

Center of the Storm


Menopause, mood, mental acuity, and hormone therapy

Emergency contraception for teens

Postpartum Contraception: Now, Not Later

Reproductive tract infections, sexually transmitted infections, or sexually transmitted diseases: “a rose by any other name…”

Are we practicing what we preach?

Be alert to VTE in hormonal contraceptive users

LARC among teens increased 15-fold, but not enough

Brain cancer and hormonal contraception

Free tools: Easy access to the US Medical Eligibility Criteria for Contraceptive Use

Alcohol consumption when pregnancy is unwanted or unintended

Latest Data on Contraceptive Use in the United States

LateBreaker sampler from Contraceptive Technology conference

Emergency Contraceptive Pill Efficacy and BMI/Body Weight

Handout on Unintended Pregnancy and Contraceptive Choice

Ask About Withdrawal (Really!)

Rules to Practice By: Safety First and Cleanliness is Close to. . .

What’s Vanity Fair Got Against the NuvaRing?

Promising New Treatment for Hepatitis C

Numbers matter, so make them simple for patients

The Recession’s Effect on Unintended Pregnancies

Lessons Learned from the Contraceptive CHOICE Project: The Hull LARC Initiative

Applying the “New” Cervical Cytology Guidelines in Your Practice

Acute Excessive Uterine Bleeding: New Management Strategies

Medical indications for IUD use in teens

Whatever happened to PID?

Update on Emergency Contraception New and Improved

LateBreaker sampler from Contraceptive Technology conference
December 2014


Impact of federal contraceptive coverage

In a 2014 national survey of 892 women with private insurance, the percentage paying $0 for contraception rose from 15% to 67% since 2012. The fees were similar for injection, vaginal ring, and IUDs. The price of pills likewise dropped substantially:

Pill cost

Cost of implementing rapid HIV testing in STD clinics

Clinics can avoid spending limited clinic resources yet still increase the number of persons identified as HIV-infected. Using data from 7 public clinics participating in a randomized trial of rapid HIV testing, Eggman et al., compared the cost of that testing with and without counseling.  The researchers found that universal rapid testing can be implemented at low cost if risk reduction counseling is not offered:

Rapid HIV testing


Prevalence of Chlamydia trachomatis infection among women

Chlamydia is the most frequently reported STD in the United States, with a prevalence of 1.8 million infections reported from the NHANES survey. The risk for infection is associated with age, race/ethnicity, income, education, and number of sexual partners.

CT prevalence


HPV vaccine effective in women older than 25

In a recent multinational double-blind randomized controlled trial of 2,264 subjects receiving HPV vaccine and 2,241 controls, the efficacy against persistent infection or CIN1+ with HPV was significant:

  • 26-35 years of age:  83.5% efficacy
  • 36-45 years of age: 77.2% efficacy

Among women who tested negative for DNA at baseline, the vaccine efficacy was similar for both seronegative and seropositive women. Rahman et al., calculate that the number of HPV infections prevented for every 100,000 women-years was 720 among women ages 26-35 and 364 among women 36-45.

61% fewer HPV cases following vaccine program in Australia

 Ever wonder how many fewer women could develop HPV infection if more girls in the United States received vaccine? Australia has a model vaccine program with high distribution. Harrison et al., analyzed 1 million patient encounters between 2000 and 2012. After the program began, the rate of genital warts among women aged 15-27 years dropped to 1.67 cases per 1,000 patient encounters, which represents a 61% drop from the 4.33 cases/1,000 encounters prior to the program. Over this period of time, no other STDs showed a significant decline, so the drop in HPV infection was unlikely due to changes in sexual behaviors.


  1. Sonfield A, Tapalies A, Jones RK, Finer LB. Impact of the federal contraceptive coverage guarantee on out-of-pocket payments for contraceptives: 2014 update. Contraception 2014, epub ahead of print.
  2. Eggman AA, Feaster DJ, Leff JA et al. the cost of implementing rapid HIV testing in sexually transmitted disease clinics in the United States. Sex Transm Dis 2014;41:545-50.
  3. Torrone E, Papp J, Weinstock H. prevalence of Chlamydia trachomatis genital infection among persons aged 14-39 years—United States, 2007-2012. MMWR 2014; 63:834-8.
  4. Rahman M, Laz T, McGrath CH, et al. correlates of human papillomavirus vaccine series completion among young adult female initiators. Hum Vaccines Immuno 2014;10:1-5.
  5. Harrison C, Britt H, Garland S, et al. decreased management of genital warts in young women in Australian program. PLoS ONE 2014;9:e105967